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Several recent reports, including twoCell StemCell papers (Zhu et al., 2009 [this issue]; Borowiak et al., 2009),
screened small molecule libraries for compounds that promote embryonic stem cell differentiation. Their
combined success helps bypass challenges associated with using natural protein factors and has revealed
insights into controlling stem cell differentiation.The ability to differentiate human embry-
onic stem cells (ESCs) or induced pluripo-
tent stem cells (iPSCs) into desired cell
types is anticipated to facilitate research
and ultimately provide therapies for
damaged or diseased human tissues.
The most successful protocols for differ-
entiating stem cells rely upon the knowl-
edge of extracellular signals and gene
regulatory factors that govern the normal
differentiation of cells in embryonic devel-
opment. Typically, the signals that induce
differentiation are mediated by intracel-
lular pathways that involve enzymatic
activities, such as for phosphorylation,
acetylation, methylation, ubiquitylation, or
for the reversal of such activities. These
enzymatic functions result in changes in
the expression or activity of regulatory
(transcription) factors, which, in turn,
govern the differentiation state of the
cell. Because signal transduction path-
ways are often activated by extracellular
protein ligands (growth factors), the field
began by using such protein-basedmate-
rials to elicit stem cell differentiation.
However, as described below, growth
factors face significant practical chal-
lenges prior to their use in deriving
commercialized stem cell-based thera-
pies, though these issues will not be
crucial for the initial application of stem
cell differentiation for research. Fortu-
nately, given the enzymatic basis of cell
differentiation, the use of synthetic small
molecules as agonists and antagonists
may surmount challenges with protein-
based approaches. Two papers in recent
issues of Cell Stem Cell (Zhu et al., 2009;
Borowiak et al., 2009) illustrate high-
throughput screening paradigms that
discover small molecule alternatives to
protein-based approaches to stem celldifferentiation. And interestingly, the small
molecule candidates provide new insights
into facilitating stem cell differentiation.
First, why bother to develop small
molecule alternatives when natural
protein effectors, refined by millions of
years of evolutionary selection, already
perform the job efficiently (see Table 1)?
In fact, there are numerous challenges
facing protein-based generation of ESC
and iPSC derivatives for human therapies.
The first is the task of producing high-
quality, purified, bioactive growth factors
from a natural source, such as via re-
combinant expression in E. coli, following
an efficient process that will be consistent
and reproducible for many years. Next,
consider the logistics and expense
required to scale protein production to
yield sufficient amounts to generate
a billion differentiated cells for a single
liver or pancreatic b cell transplant, and
multiply that value by the thousands or
tens of thousands of doses required to
make the process economically feasible
for commercial ventures. For example,
Activin A is a protein-signaling molecule
used for one of the first steps of ESC
differentiation to make endoderm, the
progenitor of liver and pancreas cells. Re-
combinant Activin A is already expensive
for differentiating millions of ESCs, much
less billions or trillions. Furthermore, any
commercial profit on stem cell-based
therapies employing growth factors will
be reduced by royalties due for product
application licensing fees. Also, the
production of the protein would have to
be redesigned under the auspices of
a ‘‘Good Manufacturing Process’’ (GMP)
to allow the product to be used in humans
(Kirouac and Zandstra, 2008). Moreover,
state of the art pancreatic and liver differ-Cell Stementiation protocols typically employ half
a dozen different growth factor effectors,
each of which faces the same hurdles
listed above. The cost issues for differen-
tiation factors are also above and beyond
those required to maintain and expand
ESC or iPSC populations and to process
the differentiated derivatives for human
therapeutic delivery (A¨hrlund-Richter
et al., 2009). Clearly, to bring stem cells
to market, so to speak, alternatives to
protein effectors must be found.
Small chemical compounds, e.g.,
under 1000 Daltons, can be easier to
manufacture than proteins, are often
entirely synthetic, are more amenable to
scale-up, and are simpler to manage
in terms of intellectual property owner-
ship, by virtue of their limited size and
complexity of production. Given the
remarkable diversity of protein surfaces
and enzyme-active sites, in principle, it
should be possible to discover small
molecules that function specifically as
agonists or antagonists of any intracellular
signaling pathway. Furthermore, chemi-
cal library compositions can be tailored
to favor cell-permeable compounds that
are known to be relatively stable and not
chemically reactive. The tricks are to
obtain a chemical library with high struc-
tural diversity so that a large range of
potential target specificities can be tested
and to devise a high-throughput screen
that reliably reports a specific develop-
mental step, such as endoderm induction
from ESCs. Such were the recent efforts
of the Melton and Schreiber (Borowiak
et al., 2009) and Schultz and Wu (Zhu
et al., 2009) laboratories.
Borowiak et al. (2009) screened a small
but diverse library of 4000 compounds for
their ability to induce the expression ofCell 4, May 8, 2009 ª2009 Elsevier Inc. 373
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Effector Type Molecular Size Origin of Target Specificity Source Manufacture Intellectual Property
Protein growth
factor
20–100 kD Millions of years
of evolution
Biological (e.g., recombinant
in E. coli, yeast, insect, or
mammalian cells)
More possible
contaminants and
complicated GMP
Multiple licenses
and royalties
Small molecule <1 kD Structural diversity
of compound library
Usually chemical
or secreted from microbes
Fewer contaminants
and simpler GMP
Fewer licenses
and royaltiesa fluorescent Sox17-dsRed reporter in
mouse ESCs. Sox17 is a marker and
an effector of endoderm differentiation
(Kanai-Azuma et al., 2002), and Activin A
treatment activated the dsRed reporter in
modified ESCs, as expected. Positive
small molecule hits were defined as
compounds that induced Sox17-dsRed
fluorescence at three standard deviations
above the levels elicited by a DMSO
solvent control, independent of Activin A
treatment. Secondary screens involved
testing hits across different mouse ESC
lines and for the capacity to generate
homogeneous clusters of Sox-17-dsRed+
epithelial cells that were negative for
extraembryonic cell markers (a typical
contaminant of endoderm differentiation
protocols). Two compounds, IDE1 and
IDE2, functioned in the submicromolar
range without observed toxicity, elicited
nearly the same whole-genome mRNA
expression profiles as seen in native endo-
derm cells from mouse embryos and
induced endoderm-like cells from human
ESCs.
IDE1 and IDE2 induce Smad2 phos-
phorylation, as observed in response to
Activin A and the related Nodal protein,
the latter being a natural inducer of endo-
derm (Conlon et al., 1994). Indeed, the
IDE compounds induce Nodal mRNA;
thus, it is possible that the IDEs primarily
induce Nodal synthesis and secretion,
leading indirectly to endoderm induction.
Importantly, the endoderm-like cells
induced by the IDEs can, when ectopi-
cally introduced, integrate in vivo into
the endodermal epithelium of mouse
embryos. Furthermore, the endoderm-
like cells induced by the IDEs could
initiate pancreatic differentiation when
exposed to Indolactam V, a different small
molecule discovered in a screen to
promote pancreatic differentiation of
human ESCs (Chen et al., 2009). Still, it
remains to be determined whether
ESC-derived endoderm and pancreatic
progenitors induced by these molecules
are programmed well enough to continue374 Cell Stem Cell 4, May 8, 2009 ª2009 Elsto differentiate into functionally useful
b cells.
Zhu et al. (2009) set out with a similar
goal: to screen 20,000 compounds for
their ability to induce mouse ESCs to
express endogenous Sox17 and not an
extraembryonic marker. However, these
authors performed their screen in the
presence of low concentrations of Activin
A. One compound, stauprimide, promoted
efficient induction of Sox17 in both mouse
and human ESCs and also helped induce
extensive endoderm differentiation
markers in the mouse ESC. Early staupri-
mide treatmentalsoenhancedsubsequent
differentiation of the resulting cells toward
hepatic and pancreatic lineages when the
treated progenitors were exposed to addi-
tional growth factors. However, further
studies showed that stauprimide did not
induce endoderm in the absence of Activin
A. Rather, the drug enhanced the ability of
theESCs togenerally embarkonanydiffer-
entiation program in response to particular
cues; e.g., the program could also lower
the differentiation threshold for neural or
mesodermal lineages.
The plot thickened when stauprimide
was found to bind NME2, a c-Myc-acti-
vating transcription factor that is highly
expressed in ESCs. Indeed, the c-Myc
transcription factor is an integral com-
ponent of the self-renewal/pluripotency
regulatory network of ESCs (Cartwright
et al., 2005; Kim et al., 2008). Knockdown
of NME2 or stauprimide treatment initially
decreased c-Myc expression without im-
pairing other pluripotency factors, though
the other factors did diminish at later time
points. Stauprimide appears to function,
at least in part, by impairing the nuclear
localization of NME2. Without nuclear
NME2, c-Myc is downregulated, which
may facilitate ESC exit from the pluripo-
tent state and enable differentiation. Yet,
the ability of c-Myc/ ESCs to remain
pluripotent (Davis et al., 1993) and the
capacity of other NME proteins to bind
MUC1 and thereby impact ESC self-
renewal (Hikita et al., 2008) suggest thatevier Inc.the effect of stauprimide on NME2 may
extend beyond c-Myc.
Regardless of the precise mechanism,
the work of Zhu et al. (2009) yields unan-
ticipated insight into ways to increase
the efficiency of stem cell differentiation.
Taken together with the discovery of small
molecules that specifically promote endo-
derm and pancreatic differentiation, the
ESC and iPSC fields are entering a new
phase in which the possibility of using
stem cells for human therapies edges
closer to feasibility.
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